S112: The Effect of Immunoglobulin Prophylaxis on Infectious Morbidity in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial

Abstract

Infections lead to substantial morbidity during treatment of acute lymphoblastic leukemia (ALL). During ALL treatment, the adaptive immune system gets severely affected, leading to, amongst other things, declining serum immunoglobulin (IgG) levels. Theoretically, one may partially overcome the infection risk by supplementing the low IgG levels with intravenous immunoglobulins (IVIG).